Physician profile
James Tolentino
NPI 1972131761
$18,069.61
in general payments reported to CMS, 2019-2025
26 companies · $6,507 in 2025
The $6,507 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $5,483 · 2024: $6,079 · 2025: $6,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,020.77 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,023.36 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $2,457.19 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $2,207.86 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,600.80 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,286.84 | 2023-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Vanda Pharmaceuticals INC. | $1,259.45 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $1,076.59 | 2023-2025 | Rexulti, Brintellix, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,030.01 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $778.73 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $679.73 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $513.21 | 2023-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $378.65 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $328.64 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Noven Therapeutics, LLC | $267.64 | 2023-2024 | Xelstrym |
| Axsome Therapeutics, INC. | $240.71 | 2024-2025 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $199.65 | 2023-2025 | Sublocade, Perseris |
| Biogen, INC. | $164.86 | 2024-2025 | Zurzuvae |
| Braeburn INC. | $120.31 | 2025 | Brixadi |
| Bausch Health US, LLC | $103.61 | 2023-2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $102.68 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $66.56 | 2025 | Cobenfy |
| Almatica Pharma LLC | $63.33 | 2024 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $44.38 | 2024-2025 | Subvenite |
| Idorsia Pharmaceuticals US INC | $37.20 | 2023 | Quviviq |
| Neos Therapeutics, Lp | $19.29 | 2025 | Exxua |
| Merck Sharp & Dohme LLC | $18.33 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tolentino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.